JPWO2023196634A5 - - Google Patents

Info

Publication number
JPWO2023196634A5
JPWO2023196634A5 JP2024559211A JP2024559211A JPWO2023196634A5 JP WO2023196634 A5 JPWO2023196634 A5 JP WO2023196634A5 JP 2024559211 A JP2024559211 A JP 2024559211A JP 2024559211 A JP2024559211 A JP 2024559211A JP WO2023196634 A5 JPWO2023196634 A5 JP WO2023196634A5
Authority
JP
Japan
Prior art keywords
cov
sars
nucleic acid
acid molecule
spike protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511756A (ja
JP2025511756A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/017945 external-priority patent/WO2023196634A2/en
Publication of JP2025511756A publication Critical patent/JP2025511756A/ja
Publication of JPWO2023196634A5 publication Critical patent/JPWO2023196634A5/ja
Publication of JP2025511756A5 publication Critical patent/JP2025511756A5/ja
Pending legal-status Critical Current

Links

JP2024559211A 2022-04-08 2023-04-07 ワクチン及び関連する方法 Pending JP2025511756A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263362710P 2022-04-08 2022-04-08
US63/362,710 2022-04-08
US202263476310P 2022-12-20 2022-12-20
US63/476,310 2022-12-20
PCT/US2023/017945 WO2023196634A2 (en) 2022-04-08 2023-04-07 Vaccines and related methods

Publications (3)

Publication Number Publication Date
JP2025511756A JP2025511756A (ja) 2025-04-16
JPWO2023196634A5 true JPWO2023196634A5 (https=) 2026-02-18
JP2025511756A5 JP2025511756A5 (https=) 2026-02-18

Family

ID=86330825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559211A Pending JP2025511756A (ja) 2022-04-08 2023-04-07 ワクチン及び関連する方法

Country Status (5)

Country Link
US (1) US20250108107A1 (https=)
EP (1) EP4504252A2 (https=)
JP (1) JP2025511756A (https=)
MX (1) MX2024012254A (https=)
WO (1) WO2023196634A2 (https=)

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US99823A (en) 1870-02-15 Improved indigo soap
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
JP4380411B2 (ja) 2004-04-30 2009-12-09 澁谷工業株式会社 滅菌方法
CN101287497B (zh) 2004-12-27 2013-03-06 赛伦斯治疗公司 涂层脂质复合体和它们的用途
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2008008230A2 (en) 2006-07-10 2008-01-17 Memsic, Inc. A system for sensing yaw rate using a magnetic field sensor and portable electronic devices using the same
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20120128767A1 (en) 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
CA2727628C (en) 2008-06-12 2018-11-27 Expres2Ion Biotechnologies Aps Improved protein expression system
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
EA036772B1 (ru) 2008-10-20 2020-12-18 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
WO2010054384A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
EP2506879A4 (en) 2009-12-01 2014-03-19 Protiva Biotherapeutics Inc PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
SG186085A1 (en) 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
ES2727583T3 (es) 2010-08-31 2019-10-17 Glaxosmithkline Biologicals Sa Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
ES2888231T3 (es) 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
JP2013545727A (ja) 2010-10-21 2013-12-26 メルク・シャープ・アンド・ドーム・コーポレーション オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
US20120101478A1 (en) 2010-10-21 2012-04-26 Allergan, Inc. Dual Cartridge Mixer Syringe
US9617461B2 (en) 2010-12-06 2017-04-11 Schlumberger Technology Corporation Compositions and methods for well completions
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012162210A1 (en) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Ring constrained cationic lipids for oligonucleotide delivery
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
JP6093710B2 (ja) 2011-11-18 2017-03-08 日油株式会社 細胞内動態を改善したカチオン性脂質
EP2788006B1 (en) 2011-12-07 2026-01-07 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
EP2788316B1 (en) 2011-12-07 2019-04-24 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
SG11201405157PA (en) 2012-02-24 2014-10-30 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
WO2013148541A1 (en) 2012-03-27 2013-10-03 Merck Sharp & Dohme Corp. DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
WO2015011633A1 (en) 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
US9593077B2 (en) 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
LT3313829T (lt) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
TWI773666B (zh) 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
ES3063077T3 (en) 2016-10-26 2026-04-15 Acuitas Therapeutics Inc Lipid nanoparticle formulations
AU2018330208B2 (en) 2017-09-08 2025-04-17 Generation Bio Co. Lipid nanoparticle formulations of non-viral, capsid-free DNA vectors
PT3688162T (pt) 2017-09-29 2024-04-23 Intellia Therapeutics Inc Formulações
AR113154A1 (es) 2017-09-29 2020-01-29 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para edición del genoma
JP7558929B2 (ja) 2018-05-11 2024-10-01 ビーム セラピューティクス インク. プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
JP7543259B2 (ja) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
EP4157345A4 (en) * 2020-05-29 2024-09-11 Board of Regents, The University of Texas System GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF
BR112023019301A2 (pt) 2021-03-22 2023-12-05 Novavax Inc Formulações de vacina de coronavírus

Similar Documents

Publication Publication Date Title
US20240207392A1 (en) Epstein-barr virus mrna vaccines
US20260000749A1 (en) Rotavirus vaccines
US12318443B2 (en) Influenza vaccine
JPWO2021213924A5 (https=)
US20230355743A1 (en) Multi-proline-substituted coronavirus spike protein vaccines
US20230108894A1 (en) Coronavirus rna vaccines
JP2023153256A (ja) SARS-COV-2 mRNAドメインワクチン
CN113453707A (zh) 用于疟疾疫苗的rna
CN113194988A (zh) 异源初次免疫加强疫苗组合物及方法
Yihunie et al. Recent advances in messenger ribonucleic acid (mRNA) vaccines and their delivery systems: a review
WO2023064993A1 (en) Chimeric betacoronavirus spike polypeptides
JPWO2023196634A5 (https=)
KR20250099770A (ko) 코로나바이러스에 대한 백신
WO2022171182A1 (zh) 一种治疗或者预防冠状病毒病突变株的疫苗试剂
AU2023378779A1 (en) Stabilized vaccines
WO2024245344A1 (zh) 预防新型冠状病毒奥密克戎突变株的mRNA疫苗
TW202444408A (zh) 疫苗
RU2023114392A (ru) Днк-кодированные наночастицы и способ их применения в качестве вакцины от коронавирусного заболевания 2019 (covid-19)
TW202446958A (zh) 核酸分子
KR20240170759A (ko) 단백질 고효율 발현용 mRNA 구조체 플랫폼
WO2024211447A1 (en) Tp508 mrnas
WO2000049041A1 (fr) Preparations proteiques
JPWO2022136370A5 (https=)